Rheumatoid Arthritis
Conditions
Keywords
rheumatoid arthritis, biological markers, remission, ultrasonography, microarray, survival analysis, T cell
Brief summary
Rheumatoid arthritis is a common condition affecting approximately 1% of the United Kingdom population; it is an autoimmune disease where the body's natural defences (the immune system) attack the body itself resulting, most notably, in joint damage and arthritis. To help prevent this, patients with rheumatoid arthritis need to take disease-modifying anti-rheumatic drugs (DMARDs). As rheumatoid arthritis is a life-long condition, these drug treatments are prescribed as long-term medications taken for many years. With successful drug treatment, many patients are able to achieve an excellent control of their disease and their arthritis can go in to remission. At present, there are no markers which can reliably predict which of these patients can reduce their drug treatment, and hence benefit from a lower risk of side effects and inconvenience, without an increase in their arthritis activity. We invite patients with stable rheumatoid arthritis to participate in this study conducted by Newcastle upon Tyne Hospitals NHS Foundation Trust in collaboration with Newcastle University and funded by the Wellcome Trust. Patients whose arthritis is confirmed as being in remission will be able to stop their DMARD medication and be monitored for a period of 6 months. Patients whose arthritis activity increases during this time will be able to restart their DMARD medication, whereas those patients whose arthritis remains in remission will be able to stay off DMARD medication. The main aim of this study is to identify clinical, ultrasound and blood markers that can predict which patients will remain in remission after stopping DMARD medication. If identified, these markers could be a useful guide to doctors and patients in the future when deciding whether to stop DMARD therapy.
Interventions
DRUGDMARD cessation
Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
Sponsors
Newcastle University
Wellcome Trust
Newcastle-upon-Tyne Hospitals NHS Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of rheumatoid arthritis made by consultant rheumatologist at least 12 months previously * Current single or combination use of methotrexate, sulphasalazine and/or hydroxychloroquine * Arthritis currently in remission, as judged clinically by referring healthcare professional * Willing to consider DMARD withdrawal
Exclusion criteria
* Use of biologic therapy within the past 6 months * Received steroids within past 3 months (enteral, parenteral or intra-articular) * Use of any DMARD other than methotrexate, sulphasalazine or hydroxychloroquine within the past 6 months (or past 12 months for leflunomide) * Current pregnancy, or pregnancy planned within next 6 months * Current participation within another clinical trial * Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time-to-flare of arthritis activity following DMARD cessation | From recruitment, assessed up to 6 months | Flare of arthritis activity defined as Disease Activity Score in 28 Joints C-Reactive Protein (DAS28-CRP) score greater than or equal to 2.4 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ultrasound biomarkers of DMARD-free remission | At recruitment | Baseline musculoskeletal ultrasound biomarkers predictive of time-to-flare of arthritis activity following DMARD cessation, including presence or absence of greyscale synovitis/tenosynovitis and erosions. |
| Genetic biomarkers of DMARD-free remission | At recruitment | Baseline signature of differential gene expression in peripheral CD4+ T cells predictive of DMARD-free remission at 6 months following DMARD cessation, as measured using RNA sequencing. |
| Clinical biomarkers predictive of DMARD-free remission | At recruitment | Baseline clinical factors predictive of time-to-flare of arthritis activity following DMARD cessation. |
| Rheumatoid arthritis disease activity | At recruitment and at 1 month, 3 months and 6 months following DMARD cessation | Measured by Disease Activity Score in 28 joints (DAS28-CRP) score. |
| Physical disability | At baseline and at 6 months following DMARD cessation | Measured by Health Assessment Questionnaire Disability Index (HAQ-DI) questionnaire |
| Cytokine biomarkers of DMARD-free remission | At recruitment | Baseline signature of differential cytokine levels in peripheral blood predictive of time-to-flare of arthritis activity, as measured using a multiplex cytokine assay. |
Countries
United Kingdom
Outcome results
None listed